Therefore, OCTs became pharmaceutically interesting: the OCT1 activity was reported to correlate with the sensitivity of tyrosine kinase inhibitors (TKI), e.g. imatinib, in patients with chronic myeloid leukemia (CML) [12-14]. The gene discussed is SLC22A1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.